A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-07

Study Completion Date

2023-07-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to conduct blood tests to measure how much LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered alone or in combination with cholestyramine in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783 with and without cholestyramine. Participation could last up to 63 days including screening period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3031207 in Healthy Subjects

NCT01449630

Healthy Volunteers

COMPLETED PHASE1

A Single Dose Study of LY3023703 in Healthy Participants

NCT01632579

Healthy Volunteers

COMPLETED PHASE1

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

NCT05860933

Healthy

COMPLETED PHASE1

To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

NCT00689247

Healthy

COMPLETED PHASE1

A Study of LY3127760 in Healthy Participants

NCT01968070

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LOXO-783 alone

Single dose of LOXO-783 administered orally.

Group Type EXPERIMENTAL

LOXO-783

Intervention Type DRUG

Administered orally.

LOXO-783 + Cholestyramine 1 hour post dose

Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 1 hour.

Group Type EXPERIMENTAL

LOXO-783

Intervention Type DRUG

Administered orally.

Cholestyramine

Intervention Type DRUG

Administered orally.

LOXO-783 + Cholestyramine 4 hours post dose

Single dose of LOXO-783 administered orally followed by a single dose of cholestyramine administered orally after 4 hours.

Group Type EXPERIMENTAL

LOXO-783

Intervention Type DRUG

Administered orally.

Cholestyramine

Intervention Type DRUG

Administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LOXO-783

Administered orally.

Intervention Type DRUG

Cholestyramine

Administered orally.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3849524

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
* Body mass index (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive